Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiov...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 01:20:14 23 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 01:20:15 23 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/23/2009 1:21:08 PM

RSS FEED

» Help

Current DateTime: 01:20:15 23 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Dec.29
9:13 AM ET
Monday, 29 Dec 2008
Are Merck's Dog Days Over?

CNBC.com

Here at CNBC we've got a team of folks who compile market stats and regularly send them out via blast emails. They slice and dice the stuff every which way, and while it's very helpful and insightful for a lot of our staffers, I confess I usually instantly delete the messages since much of it doesn't pertain to my beat.

But for some reason last Friday evening — maybe because I was bored on the train ride home and I don't pass the time playing "Brickbreaker" — I opened and paged down one of the stock-stat emails.

It came as no surprise that General Motors is the December dog of the Dow — down more than 30 percent so far this month.

But I was definitely caught off guard when I saw that Merck (Merck!) is the best performing Dow component in December, with less than three trading days left. MRK shares [MRK  Loading...      ()   ] are up eight-and-a-half percent.

Could the drugmaker's annual analyst meeting earlier this month have been a catalyst? Or did investors simply decide the stock's cheap with a high dividend yield?

Check back later today when I will reveal the best-performing Nasdaq 100 stock year-to-date. The index is down 42 percent in 2008. But the top stock is up nearly 27 percent. Hint: It's a biopharma stock.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 01:14:29 23 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 10:08:24 23 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 10:23:55 23 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:08:16 23 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters